1.A Case of Aortic Stenosis Secondary to Bicuspid Aortic Valve Associated with Klippel-Feil Syndrome Treated by Aortic Valve Replacement.
Shigeru Ohki ; Susumu Ishikawa ; Akio Ohtaki ; Toru Takahashi ; Yasushi Satoh ; Tetsuya Koyano ; Toshiharu Yamagishi ; Takashi Ogino ; Satoshi Ohki ; Yasuo Morishita
Japanese Journal of Cardiovascular Surgery 1997;26(3):200-203
A 52-year-old male was diagnosed as having aortic stenosis secondary to a bicuspid aortic valve associated with Klippel-Feil syndrome. Aortic valve replacement was successfully performed without any problems in the surgical or anesthesiological management. Only five such cases including ours, who underwent cardiac surgery have been reported. It is possible to perform cardiac surgery for patients with Klippel-Feil syndrome of their cardiac function can be well preserved.
2.Risk Factors in Arteriosclerosis Obliterans: A Comparison Study with Ischemic Heart Disease.
Satoshi Ohki ; Hisao Kumakura ; Shouichi Tange ; Shuichi Ichikawa ; Yoshio Ohyama ; Susumu Ishikawa ; Yasuo Morishita
Japanese Journal of Cardiovascular Surgery 1997;26(1):11-15
In order to elucidate risk factors in arteriosclerosis obliterans (ASO), histories and physical and laboratory findings were reviewed in 163 patients with ASO, and the results were compared with ischemic heart disease (IHD) patients. Patients with ASO were much older and smoked more than patients with IHD. Such complications as hypertension, cerebrovascular disease were significantly more frequent in ASO patients than in IHD patients. On the other hand, the levels of serum total cholesterol, triglycerides, Apo A-II and Apo B were significantly lower in ASO patients than in IHD patients, although lipoprotein(a) tended to be higher in ASO. In ASO, remnant-like particles cholesterol tended to be higher when other presumable atherosclerotic risk factors were absent. The present results indicate that male gender, aging, smoking habit, hypertension and cerebrovascular disease are major risk factors in ASO patients. Although abnormal lipid metabolism may contribute to the development of ASO, we postulate that it plays a less significant role in IHD.
3.Long-term Results of Surgical Treatment of Abdominal Aortic Aneurysm.
Satoshi Ohki ; Susumu Ishikawa ; Takashi Ogino ; Akio Ohtaki ; Toru Takahashi ; Yutaka Hasegawa ; Toshiharu Yamagishi ; Syuji Sakata ; Jun Murakami ; Yasuo Morishita
Japanese Journal of Cardiovascular Surgery 1997;26(5):298-301
A follow-up study of 98 patients undergoing abdominal aortic aneurysm (AAA) repair for 44 months, ranging 2 to 113 months, revealed no difference in 5-year actuarial survival between patients aged 75 or older and patients aged less than 75. The 5-year actuarial survival of ruptured and nonruptured AAA cases was 469% and 71.2%, respectively (p<0.01). Late deaths after the repair of ruptured AAA were all due to atherosclerotic diseases. During a follow-up period after AAA repair, 9 patients were diagnosed as having malignant diseases with a fatal outcome in 6. Careful attention to atherosclerotic and malignant diseases is indispensable for follow-up management after AAA repair.
4.Risk Factors for Acute Cholangitis Caused by Enterococcus faecalis and Enterococcus faecium
Yuki KARASAWA ; Jun KATO ; Satoshi KAWAMURA ; Kentaro KOJIMA ; Takamasa OHKI ; Michiharu SEKI ; Kazumi TAGAWA ; Nobuo TODA
Gut and Liver 2021;15(4):616-624
Background/Aims:
Acute cholangitis (AC) is a potentially life-threatening bacterial infection, and timely antimicrobial treatment, faster than that achieved with bacterial cultures, is recommended.Although the current guidelines refer to empirical antimicrobial treatment, various kinds of antimicrobial agents have been cited because of insufficient analyses on the spectrum of pathogens in AC. Enterococcus spp. is one of the most frequently isolated Gram-positive bacteria from the bile of patients with AC, but its risk factors have not been extensively studied. This study aimed to analyze the risk factors of AC caused by Enterococcus faecalis and Enterococcus faecium.
Methods:
Patients with AC who were hospitalized in a Japanese tertiary center between 2010 and 2015 were retrospectively analyzed. Patients’ first AC episodes in the hospital were evaluated.
Results:
A total of 266 patients with AC were identified. E. faecalis and/or E. faecium was isolated in 56 (21%) episodes of AC. Prior endoscopic sphincterotomy (EST), the presence of a biliary stent, prior cholecystectomy, and past intensive care unit admission were more frequently observed in AC patients with E. faecalis and/orE. faecium than in those without such bacteria. Prior EST was identified as an independent risk factor for AC caused by E. faecalis and/or E. faecium in the multivariate analysis.
Conclusions
Given the intrinsic resistance of E. faecalis and E. faecium to antibiotics, clinicians should consider empirical therapy with anti-enterococcal antibiotics for patients with prior EST.
5.Risk Factors for Acute Cholangitis Caused by Enterococcus faecalis and Enterococcus faecium
Yuki KARASAWA ; Jun KATO ; Satoshi KAWAMURA ; Kentaro KOJIMA ; Takamasa OHKI ; Michiharu SEKI ; Kazumi TAGAWA ; Nobuo TODA
Gut and Liver 2021;15(4):616-624
Background/Aims:
Acute cholangitis (AC) is a potentially life-threatening bacterial infection, and timely antimicrobial treatment, faster than that achieved with bacterial cultures, is recommended.Although the current guidelines refer to empirical antimicrobial treatment, various kinds of antimicrobial agents have been cited because of insufficient analyses on the spectrum of pathogens in AC. Enterococcus spp. is one of the most frequently isolated Gram-positive bacteria from the bile of patients with AC, but its risk factors have not been extensively studied. This study aimed to analyze the risk factors of AC caused by Enterococcus faecalis and Enterococcus faecium.
Methods:
Patients with AC who were hospitalized in a Japanese tertiary center between 2010 and 2015 were retrospectively analyzed. Patients’ first AC episodes in the hospital were evaluated.
Results:
A total of 266 patients with AC were identified. E. faecalis and/or E. faecium was isolated in 56 (21%) episodes of AC. Prior endoscopic sphincterotomy (EST), the presence of a biliary stent, prior cholecystectomy, and past intensive care unit admission were more frequently observed in AC patients with E. faecalis and/orE. faecium than in those without such bacteria. Prior EST was identified as an independent risk factor for AC caused by E. faecalis and/or E. faecium in the multivariate analysis.
Conclusions
Given the intrinsic resistance of E. faecalis and E. faecium to antibiotics, clinicians should consider empirical therapy with anti-enterococcal antibiotics for patients with prior EST.
6.Recent Development of Techniques and Devices in Colorectal Endoscopic Submucosal Dissection.
Hiroya MIZUTANI ; Satoshi ONO ; Daisuke OHKI ; Chihiro TAKEUCHI ; Seiichi YAKABI ; Yosuke KATAOKA ; Itaru SAITO ; Yoshiki SAKAGUCHI ; Chihiro MINATSUKI ; Yosuke TSUJI ; Keiko NIIMI ; Shinya KODASHIMA ; Nobutake YAMAMICHI ; Mitsuhiro FUJISHIRO ; Kazuhiko KOIKE
Clinical Endoscopy 2017;50(6):562-568
Colorectal endoscopic submucosal dissection (ESD) is now a well-established endoscopic treatment for early-stage colorectal neoplasms, especially in Asian countries, including Japan. Despite the spread of colorectal ESD, there are still situations in which achieving successful submucosal dissection is difficult. Various novel techniques and devices have been developed to overcome these difficulties, and past reports have shown that some of these strategies can be applied to colorectal ESD. We review several recent developments in the field. The techniques reviewed include the pocket creation method and traction methods and the devices reviewed include the overtube with balloon and electrosurgical knives with water-jet function. These improved techniques and devices can facilitate safer, more reliable ESDs and expand its applicability and acceptability all over the world.
Asian Continental Ancestry Group
;
Colorectal Neoplasms
;
Humans
;
Japan
;
Methods
;
Traction
7.Crizotinib versus Chemotherapy in Asian Patients with ALK-Positive Advanced Non-small Cell Lung Cancer.
Makoto NISHIO ; Dong Wan KIM ; Yi Long WU ; Kazuhiko NAKAGAWA ; Benjamin J SOLOMON ; Alice T SHAW ; Satoshi HASHIGAKI ; Emiko OHKI ; Tiziana USARI ; Jolanda PAOLINI ; Anna POLLI ; Keith D WILNER ; Tony MOK
Cancer Research and Treatment 2018;50(3):691-700
PURPOSE: Crizotinib has demonstrated superior progression-free survival (PFS) and objective response rates (ORRs) versus chemotherapy in previously treated and untreated patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We report the safety and efficacy of crizotinib in Asian subpopulations of two global phase III trials. MATERIALS AND METHODS: This analysis evaluated previously treated and untreated patients in two randomized, open-label phase III trials of crizotinib versus chemotherapy in ALK-positive advanced NSCLC in second-line (PROFILE 1007) and first-line settings (PROFILE 1014). Efficacy and safety were analyzed by race in the intention-to-treat and “as-treated” populations for efficacy and safety endpoints, respectively. RESULTS: In previously treated (n=157) and untreated (n=157) Asian patients, PFS was statistically significantly longer with crizotinib versus chemotherapy (hazard ratio for PFS, 0.526; 95% confidence interval, 0.363 to 0.762; p < 0.001 and hazard ratio, 0.442; 95% confidence interval, 0.302 to 0.648; p < 0.001, respectively). Similar antitumor activity was seen in the non-Asian and overall populations. ORRs were statistically significantly higher with crizotinib versus chemotherapy in both Asian and non-Asian previously treated and untreated patients (p < 0.05). The most common treatment-emergent adverse events (any grade)with crizotinib were vision disorder, diarrhea, and nausea, which were observed at a comparable incidence across Asian and non-Asian populations, irrespective of previous treatment status. Most adverse events were mild to moderate in severity. CONCLUSION: These data, currently the only analysis showing Asian and non-Asian populations in the same study, support the efficacy and safety of crizotinib in Asian patients with previously treated or untreated ALK-positive advanced NSCLC.
Asia
;
Asian Continental Ancestry Group*
;
Carboplatin
;
Carcinoma, Non-Small-Cell Lung*
;
Cisplatin
;
Continental Population Groups
;
Diarrhea
;
Disease-Free Survival
;
Drug Therapy*
;
Humans
;
Incidence
;
Lymphoma
;
Nausea
;
Pemetrexed
;
Phosphotransferases
;
Vision Disorders
8.Xanthogranulomatous Inflammation of the Aortic Aneurysm Wall after Endovascular Aortic Repair for Abdominal Aortic Aneurysm
Shuichi OKONOGI ; Satoshi OHKI ; Kiyomitsu YASUHARA ; Ayako NAGASAWA ; Takao MIKI ; Ryo YAMAGUCHI ; Yusuke KATO ; Tamiyuki OBAYASHI
Japanese Journal of Cardiovascular Surgery 2023;52(2):114-117
A 77-year-old woman underwent endovascular abdominal aortic repair (EVAR) for an abdominal aortic aneurysm (AAA).Five years after surgery, she visited the hospital with the chief complaint of a fever. Enhanced computed tomography (CT) showed enlargement of the AAA around the stent-graft and a mass, which was suspected to be an abscess, outside the aneurysm. A blood test revealed a high level of inflammatory response. The patient was diagnosed with infectious AAA. She received antibiotics; however, the inflammatory response did not completely improve. A second CT scan revealed that the suspected abscess had a spreading tendency. The patient was referred to our hospital for a highly suspected stent-graft infection. We performed Y-graft replacement using a rifampicin-immersed graft, and as much as possible of the wall around the aortic aneurysm was removed. The inflammatory response improved rapidly after the operation, and the patient was discharged 15 days later. According to the results of a pathological examination, a diagnosis of xanthogranulomatous inflammation and fibrosis was made. Here, we report a rare case of xanthogranulomatous inflammation of the aortic aneurysm wall after EVAR.
9.Impact of the Sensitivity to Empiric Antibiotics on Clinical Outcomes after Biliary Drainage for Acute Cholangitis
Satoshi KAWAMURA ; Yuki KARASAWA ; Nobuo TODA ; Yousuke NAKAI ; Chikako SHIBATA ; Ken KUROKAWA ; Junya ARAI ; Kazuyoshi FUNATO ; Shigeyuki KUROSAKI ; Shuya MAESHIMA ; Mayuko KONDO ; Kentaro KOJIMA ; Takamasa OHKI ; Michiharu SEKI ; Kazuhiko KOIKE ; Kazumi TAGAWA
Gut and Liver 2020;14(6):842-849
Background/Aims:
Empiric antibiotics are given in combina-tion with biliary drainage for acute cholangitis but sometimes turn out to be insensitive to microorganisms in blood and bile. Clinical outcomes were compared according to sensitiv-ity to microorganisms detected in blood and bile culture to evaluate the impact of sensitivity to empiric antibiotics in cholangitis.
Methods:
Consecutive patients who underwent biliary drainage for acute cholangitis were retrospectively studied. Clinical outcomes such as 30-day mortality, length of hospital stay and high care unit stay, organ dysfunction and duration of fever were compared in three groups: group A (sensitive to both blood and bile culture), group B (sensitive to blood culture alone) and group C (insensitive to both blood and bile culture).
Results:
Eighty episodes of cholangitis were classified according to sensitivity results: 42, 32 and six in groups A, B and C. Escherichia coli and Klebsiella were two major pathogens. There were no significant differences in 30-day mortality rate (7%, 0%, and 0%, p=0.244), length of hospital stay (28.5, 21.0, and 20.5 days, p=0.369), organ dysfunction rate (14%, 25%, and 17%, p=0.500), duration of fever (4.3, 3.2, and 3.5 days, p=0.921) and length of high care unit stay (1.4, 1.2, and 1.7 days, p=0.070) in groups A, B and C. Empiric antibiotics were changed in 11 episodes but clinical outcomes appeared to be non-inferior even in 31episodes of cholangitis who were on inadequate antibiotics throughout the course.
Conclusions
Sensitivity of empiric antibiotics was not associated with clinical outcomes in acute cholangitis.